伴POD24的滤泡性淋巴瘤的治疗模式与结局:LEO联盟分析
研究纳入220例发生POD24且保留滤泡性淋巴瘤组织学的患者,评估其治疗模式与结局。POD24后治疗异质性大,无单一方案占比超过25%;总缓解率64%,完全缓解率39%,中位无事件生存期9.8个月,5年总生存率71%;年龄>70岁及诊断时FLIPI高危者总生存较差。
要点
- POD24后治疗选择分散,无单一方案占比超过25%。
- POD24后总缓解率64%,完全缓解率39%,中位无事件生存期9.8个月。
- 年龄>70岁和诊断时FLIPI高危与较差总生存相关。
核心结论
- POD24后无标准治疗,各治疗类别疗效无突出优势,死亡原因以淋巴瘤相关为主。
- 本研究是描述POD24当代治疗模式的最大队列之一,为设计和解读前瞻性临床试验提供数据集。
研究设计与样本
- 基于淋巴瘤流行病学结局联盟真实世界证据(LEO Consortium for Real World Evidence)的学术队列分析。
- 纳入220例发生POD24且保留滤泡性淋巴瘤组织学的患者。
主要发现
- POD24后治疗异质性大,无治疗类别占总治疗比例超过25%。
- 初始接受苯达莫司汀-利妥昔单抗治疗者中,R-CHOP是主要二线选择(48%)。
- 初始接受R-CHOP治疗者中,侵袭性挽救治疗是主要二线选择(38%)。
- POD24后治疗的总缓解率为64%(95%CI 56-70),完全缓解率为39%(95%CI 32-46)。
- POD24后治疗的中位无事件生存期为9.8个月(95%CI 7.3-12.1),5年总生存率为71%(95%CI 65-78)。
关键数值与推荐
- 年龄>70岁者总生存较差(HR 2.31;95%CI 1.27-4.20)。
- 诊断时FL国际预后指数(FLIPI)高危者总生存较差(HR 2.10;95%CI 1.23-3.60)。
- POD24事件时保留滤泡组织学者的5年转化累积发生率为1.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an academic-based cohort from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence, we evaluated patterns of care and outcomes for 220 patients with FL with POD24 and retained FL histology. Therapy after POD24 was heterogeneous, with no treatment category accounting for >25% of the total. Among patients initially treated with bendamustine-rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) was the predominant second-line choice (48%). Among patients initially treated with R-CHOP, aggressive salvage therapy was the predominant second-line choice (38%). Overall response rate to therapy after POD24 was 64% (95% confidence interval [CI], 56-70); complete response rate was 39% (95% CI, 32-46). The median event-free survival for therapy after POD24 was 9.8 months (95% CI, 7.3-12.1); 5-year overall survival (OS) was 71% (95% CI, 65-78). OS was inferior for patients aged >70 years (hazard ratio [HR], 2.31; 95% CI, 1.27-4.20) and those with high-risk FL International Prognostic Index scores at diagnosis (HR, 2.10; 95% CI, 1.23-3.60). No treatment category stood out with more favorable results. Cause of death was predominantly lymphoma related. Patients with follicular histology at their POD24 event had a low cumulative incidence of transformation (1.1% at 5 years). Our study is among the largest cohorts describing contemporary patterns of care for patients with POD24, providing a focused data set useful for interpreting and designing prospective clinical trials in this population.
引用
- Day JR, Larson MC, Durani U, et al. Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025. PMID: 39602301. doi:10.1182/bloodadvances.2024014053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。